Patent ID: 8722344

Claim:
A method for administering or prescribing a therapeutic agent targeting cardiovascular disease to a human patient based on an elevated level of one or more oxidized apoA-1 biomolecules comprising: determining, based on an assay of a biological sample from a human patient, that said human patient has elevated levels of one or more oxidized apoA-I-related biomolecules selected from oxidized apoA-1, and an oxidized apoA-I peptide fragment, wherein said biological sample is a blood sample, serum sample, or a plasma sample, wherein said oxidized apoA-1 and the oxidized apoA-1 from which said oxidized apoA-1 peptide fragments are derived, have reduced cholesterol efflux stimulating activity as compared to un-oxidized apoA-1; and administering or prescribing a therapeutic agent targeting cardiovascular disease to said human patient based on said elevated level of said one or more apoA-I-related oxidized biomolecules in said biological sample.